CHILDREN'S MEDICAL CENTER CORPORATION Patent applications |
Patent application number | Title | Published |
20160136292 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. | 05-19-2016 |
20160106782 | WOUND HEALING AND TISSUE ENGINEERING - The present invention is directed to wound healing scaffolds cografted with a population of stem cells, wherein the population of stem cells are ABCB5+ stem cells. The scaffolds are, for instance, collagen glycosaminoglycan scaffolds. | 04-21-2016 |
20160090404 | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS - The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from | 03-31-2016 |
20160067276 | HOLLOW PARTICLES ENCAPSULATING A BIOLOGICAL GAS AND METHODS OF USE - Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described. | 03-10-2016 |
20160052981 | REGULATORS OF NFAT - Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein. Methods of identifying an agent that modulates intracellular calcium, methods to screen for an agent that modulates NFAT regulator function, methods to diagnose unexplained immunodeficiency in a subject, and methods for identifying an agent for treating or preventing a disease or disorder associated with a NFAT regulator protein or calcium signaling are also disclosed. | 02-25-2016 |
20160038724 | SHUNT FLUSHER - A device and system for flushing a shunt catheter utilizes the available cerebrospinal fluid (CSF) to flush a blocked catheter. The CSF is pressurized to a predetermined amount and then allowed to suddenly, rapidly and forcefully purge any occlusions. The rapid release of CSF produces flow jets from the catheter pores into the ventricle. This impulse, or “cough”, will push and divert choroid plexus and/or other blockages away from the pores. The device and system may then be allowed to refill at a slow rate, thus reducing the possibility of rapid suction of fluid back into the system and the attendant possibility of drawing the choroid plexus back into the pores. The catheter at the proximal end may also include back-up pores that can be opened to restart flow from the ventricle should the primary pores remain blocked after a flushing attempt. | 02-11-2016 |
20160032317 | COMPOSITIONS AND METHODS FOR REPROGRAMMING HEMATOPOIETIC STEM CELL LINEAGES - Provided herein are compositions, methods, and kits for hematopoietic stem cell induction or for reprogramming cells to the multipotent state of hematopoietic stem cells. In some embodiments, the compositions comprise at least one HSC inducing factor. Such compositions, methods and kits can be used for inducing hematopoietic stem cells in vitro, ex vivo, or in vivo, as described herein, and these induced hematopoietic stem cells can be used in regenerative medicine applications and therapies. | 02-04-2016 |
20160032242 | A ROLE FOR THE PERLMAN SYNDROME EXONUCLEASE DIS3L2 IN THE LIN28-LET-7 PATHWAY - The 3′-5′ exonuclease, Dis3l2, is responsible for the decay of uridylated pre-let-7 miRNA. Biochemical reconstitution assays revealed that 3′ oligouridylation stimulates Dis3l2 activity in vitro, and knockdown of Dis3l2 in mouse embryonic stem cells leads to the stabilization of pre-let-7 miRNA. These Dis3l2-depleted stem cells displayed elevated expression of pluripotency genes and delayed differentiation. The present disclosure establishes 3′ oligouridylation as an RNA decay signal for Dis3l2 and identifies the first physiological RNA substrate of this exonuclease. | 02-04-2016 |
20160030596 | GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE - Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described. | 02-04-2016 |
20160015533 | METHODS AND APPARATUSES FOR TREATING VESSELS - Methods and apparatuses relate to treating vessels that have developed an aneurysm or vessels that are expected to develop an aneurysm (e.g., aortic aneurysm). The device may include a conduit having one or more coupling members that serve to couple the conduit and the vessel together. The conduit and coupling member(s) may cooperate to apply an inward radial force (e.g., physical pulling of the vessel wall inward) on the vessel wall, substantially preventing vessel enlargement. In some embodiments, coupling members are disposed at a midpoint region between opposite ends of the conduit, such as regularly along the length of the conduit. When deployed, the device reduces the risk of excessive vessel enlargement which may otherwise lead to undesirable rupture or dissection of the vessel. | 01-21-2016 |
20160003842 | GLYCOPEPTIDE IDENTIFICATION - A system including a device with at least one processor and memory storing computer-executable instructions that, when executed by the at least one processor, perform a method of identifying glycopeptides in a sample, the method including, analyzing a mass spectrum of the sample to identify at least one portion of the mass spectrum having at least one characteristic of mass spectra indicative of presence of glycopeptides, identifying the glycopeptides in the sample based on the at least one identified portion; and analyzing at least one glycopeptide of the identified glycopeptides. | 01-07-2016 |
20150374811 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE - The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumoccocus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a thereapeutic immune response to an infected individual. | 12-31-2015 |
20150374756 | ABCB5(+) STEM CELLS FOR TREATING OCULAR DISEASE - Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface. | 12-31-2015 |
20150367030 | COLLAGEN SCAFFOLDS - Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally methods and related kits for the repair of articular tissue using the collagen material are provided. | 12-24-2015 |
20150342609 | METHODS AND APPARATUSES FOR APPLYING TENSILE FORCE TO TISSUE - Methods and apparatuses relate to an implantable apparatus that may be used to apply tensile force(s) to one or more tissue regions (e.g., proximal and distal esophagus portions, bowel, other conduits) within the body. Such tensile force(s) may cause stretch and/or growth of the tissue region(s). In various embodiments, support members (e.g., suture rings) may be attached to respective tissue regions. The support members may accommodate attachment of a number of sutures along the tissue region. Upon suitable attachment of the support member(s) to the tissue region(s), the actuator may be coupled to the support member(s). The actuator may then be controlled so as to cause relative movement between the support members toward or away from one another. Such movement may result in the application of appropriate tensile force(s) to the tissue region(s). | 12-03-2015 |
20150307867 | TARGETING BCL11A DISTAL REGULATORY ELEMENTS FOR FETAL HEMOGLOBIN REINDUCTION - Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels. | 10-29-2015 |
20150293099 | DIAGNOSIS AND TREATMENT OF CANCER - Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof. | 10-15-2015 |
20150272467 | ESTIMATION OF INCOHERENT MOTION PARAMETERS FROM DIFFUSION-WEIGHTED MRI DATA - Some aspects provide a method of determining a set of parameter estimates for an incoherent motion model from diffusion-weighted magnetic resonance data of a portion of a biological body. The method comprises determining a first set of parameter estimates for a plurality of voxels associated with one or more images based, at least in part, on the diffusion-weighted magnetic resonance data, determining a second set of parameter estimates by stochastically perturbing the first set of parameter estimates, determining a third set of parameter estimates based, at least in part, on the first set of parameter estimates and the second set of parameter estimates, and determining whether at least one criterion associated with the third set of parameter estimates is satisfied. | 10-01-2015 |
20150253410 | DIFFUSION-WEIGHTED MRI USING MULTIPLE B-VALUES AND CONSTANT ECHO TIME - Methods and apparatus for acquiring diffusion-weighted images. The method comprises selecting a plurality of diffusion gradient vectors, wherein at least two of the plurality of diffusion gradient vectors correspond to different non-zero b-values. The method further comprises determining a gradient strength for each of the plurality of diffusion gradient vectors such that an echo image time (TE) remains constant when gradients corresponding to each of the plurality of diffusion gradient vectors are applied. The method further comprises acquiring the diffusion-weighted images using a gradient encoding scheme including the gradients corresponding to each of the plurality of gradient vectors. | 09-10-2015 |
20150216436 | DETECTION OF EPILEPTOGENIC BRAINS WITH NON-LINEAR ANALYSIS OF ELECTROMAGNETIC SIGNALS - Methods and apparatus for identifying and using at least one nonlinear feature determined from multiscale electroencephalography (EEG) data to evaluate an epileptogenicity level of a patient is described. A multiscale algorithm is applied to EEG data recorded from the patient to produce scaled EEG data. At least one nonlinear feature value for the received EEG data and/or the scaled EEG data is determined and the at least one nonlinear feature value is used, at least in part, to evaluate the epileptogenicity level of the patient. | 08-06-2015 |
20150190363 | METHODS TO TREAT NEURODEGENERATIVE DISEASES - The present invention is based on the discovery that motor neurons derived from patients with a neuro-degenerative disease have decreased delayed rectifier potassium current and increased persistent sodium current compared to motor neurons derived from control healthy individuals. The present invention is also based on the discovery that the class of compounds known as “potassium channel openers” can be used to treat neurodegenerative diseases, including ALS, Parkinson's disease, Alzheimer's disease, epilepsy, and pain. | 07-09-2015 |
20150152385 | TISSUE CONSTRUCTS AND USES THEREOF - Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns. | 06-04-2015 |
20150150959 | BACTERIAL BIOFILM MATRIX AS A PLATFORM FOR PROTEIN DELIVERY - Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins. Some aspects of this disclosure provide compositions and methods useful for the generation of vaccines and the vaccination of subjects, for delivering molecules of interest to a target site, for example, a surface, for purification of molecules of interest, for example, from bioreactors comprising engineered bacteria as provided herein, and for bioremediation applications, such as the cleanup of environmental pollutants. | 06-04-2015 |
20150132321 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 - The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via β1 integrin activation. | 05-14-2015 |
20150132312 | SYSTEMS AND METHODS FOR EXTRACORPOREAL BLOOD MODIFICATION - The present invention generally relates to systems and methods for targeted removal of a substance or biomolecule such as a protein from a biological fluid, such as blood. In some cases, the blood may be withdrawn from a subject, treated, and returned to the subject. Previous techniques for removal of biological materials from blood, such as hemodialysis and plasmapheresis, were generally non-specific (i.e., they removed a multitude of proteins/toxins from the blood). By contrast, novel methods and devices described herein are capable of removing specific or single substances such as proteins from biological fluids such as blood in a specific manner. Such highly specific protein removal has a broad array of clinical applications, including treatment of inflammatory conditions and autoimmune diseases. | 05-14-2015 |
20150104406 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. | 04-16-2015 |
20150072937 | Chimeric Peptides for the Regulation of GTPases - Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer. The present invention generally relates to chimeric peptides capable of regulating GTPases, and more particularly, to methods of targeting individual GTPases by using GTPase-activating proteins. Such proteins may be used for the treatment of cancers and other GTPase-related diseases. This invention relates to nucleic acid molecules and the encoded GTPase activating proteins, and variants thereof, and to the use of these molecules in the characterization, diagnosis, prevention, and treatment of cell signaling, immune, and cell proliferative disorders, particularly cancer. Disclosed herein are compounds and methods for regulating transcription of a selected gene. | 03-12-2015 |
20150056174 | SELF-CLEAVING RIBOZYMES AND USES THEREOF - In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs. | 02-26-2015 |
20150037814 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzymes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of cancer, metastatic cancer, and obstructive and degenerative conditions. | 02-05-2015 |
20150037362 | MODULATORS OF ANTIVIRAL SIGNALING PATHWAYS AND THERAPEUTIC USES THEREOF - The invention provides methods, compositions, and kits featuring novel RIG-I like receptor activators or inhibitors for use in preventing or treating virus infection or autoimmune disease. | 02-05-2015 |
20150031049 | METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals. | 01-29-2015 |
20150023927 | CONVERSION OF SOMATIC CELLS INTO FUNCTIONAL SPINAL MOTOR NEURONS, AND METHODS AND USES THEREOF - The present invention provides methods of transdifferentiation of somatic cells, for example, directly converting a somatic cell of a first cell type, e.g., a fibroblast into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for converting a somatic cell, e.g., a fibroblast into a motor neuron, e.g., an induced motor neuron (iMN) with characteristics of a typical motor neuron. The present invention also relates to an isolated population comprising induced motor neurons (iMNs), compositions and their use in the treatment of motor neuron diseases such as ALS and SMA. In particular, the present invention relates to direct conversion of a somatic cell to an induced motor neuron (iMN) having motor neuron characteristics by increasing the protein expression of at least three motor-neuron inducing (MN-inducing) factors selected from Lhx3, Ascl1, Brn2, Myt1l, Isl1, Hb9, Ngn2 or NeuroD1 in a somatic cell, e.g., a fibroblast to convert the fibroblast to an induced motor neuron (iMN) which exhibits at least two characteristics of an endogenous motor neuron. | 01-22-2015 |
20140370526 | DETECTING INCLUSION BODY MYOSITIS - Methods, devices, kits and systems for diagnosing inclusion body myositis (IBM) are provided. Methods, devices, kits and systems involves detecting the presence and/or level of autoantibodies that are reactive against at least a ˜43 kilodalton (kDa) protein or ˜43 kDa protein band from a muscle lysate or a mammalian cell lysate, or autoantibodies that are reactive against a cytosolic 5′-nucleotidase 1A protein (NT5C1A), or a cytosolic 5′-nucleotidase 1B protein (NT5C1B), or a NT5C1B isoform thereof, or a peptide fragment thereof, an isolated peptide thereof or a fusion protein comprising an isolated peptide of NT5C1A or NT5C1B. Such autoantibodies are only found in IBM patients and not in patients with other myopathies. | 12-18-2014 |
20140369984 | BIOMATERIAL FOR ARTICULAR CARTILAGE MAINTENANCE AND TREATMENT OF ARTHRITIS - The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery. | 12-18-2014 |
20140356882 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs. | 12-04-2014 |
20140350352 | SYSTEM AND METHOD OF ASSESSING STABILITY OF PATIENTS - In one embodiment, a technique for assessing a stability of a patient is provided. In particular, a plurality of estimated trends for each physiological variable of a patient are calculated by utilizing a plurality of physiological variables from a plurality of medical devices and a plurality of target ranges for each physiological variable. These trends are then used to calculate dynamically a single stability value over time of the patient based the target ranges input by a user for each physiological variable in relation to the estimated trends. In particular, this stability value a single value that accounts for and reflects the stability/acuity of a plurality of physiological variables to indicate quickly to physicians the stability of the patient. | 11-27-2014 |
20140341949 | VACCINE - The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol. | 11-20-2014 |
20140336065 | DETECTION OF HUMAN SOMATIC CELL REPROGRAMMING - The methods and kits described herein are based, in part, to the discovery of a phenotype representing a fully-reprogrammed iPS cell and several reprogramming intermediates. The methods and kits described herein permit identification of fully-reprogrammed iPS cells and further permits one of skill in the art to monitor the emergence of iPS cells during the reprogramming process. The methods/kits can also be performed using real time using live cell imaging. Also described herein are methods for screening candidate reprogramming agents by monitoring the emergence of fully-reprogrammed iPS cells in the presence and absence of such an agent. | 11-13-2014 |
20140329879 | DIAGNOSIS AND TREATMENT OF TAXANE-RESISTANT CANCERS - Provided herein are methods and assays relating to the diagnosis and treatment of a taxane-resistant cancer. Such methods and assays comprise determining the level of expression of miR-135a in a biological sample from a subject having or suspected of having a taxane-resistant cancer or from a subject that was or is being treated with a taxane anti-cancer agent. Also provided herein are methods for treating such cancers by administering an inhibitor of the miR-135a pathway and a taxane to a subject in need thereof. | 11-06-2014 |
20140328858 | LIN28-MEDIATED CONTROL OF LET-7 BIOGENESIS - The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3′ terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA. | 11-06-2014 |
20140303031 | METHODS AND COMPOSITIONS FOR CHARACTERIZING AUTISM SPECTRUM DISORDER BASED ON GENE EXPRESSION PATTERNS - The invention relates to methods and kits for characterizing and diagnosing autism spectrum disorder in an individual based on gene expression levels. | 10-09-2014 |
20140302025 | VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS - Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-bind ing protein. | 10-09-2014 |
20140301996 | METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES - The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from | 10-09-2014 |
20140301969 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. | 10-09-2014 |
20140294727 | PEPTIDES FOR ASSISTING DELIVERY ACROSS THE BLOOD BRAIN BARRIER - The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders. | 10-02-2014 |
20140288440 | SYSTEMS AND METHODS FOR QUANTITATIVE CAPNOGRAM ANALYSIS - Systems and methods are disclosed herein for quantitatively identifying a patient's physiological state based on one or more capnograms. One or more capnograms are acquired, each capnogram being associated with a patient and including one or more respiratory cycles, and one or more features from the one or more respiratory cycles are extracted. One or more classifiers are provided based on the one or more extracted features, and each classifier is used to select a physiological state from one or more candidate physiological states for each of the one or more respiratory cycles. For each of the selected physiological states, a likelihood value is determined, and a physiological state of the patient is determined based on the likelihood values. | 09-25-2014 |
20140271657 | COMBINATORIAL COMPOSITIONS AND METHODS OF TREATING HEMOGLOBINOPATHIES - Provided herein are compositions and methods for increasing fetal hemoglobin expression (HbF) for the treatment and/or amelioration of the symptoms of a hemoglobinpathy in a mammal. The compositions comprise a combination of one or more inhibitors of BCL11A expression or activity with epigenetic modifiers, such as inhibitors of DNA methylation and/or one or more inhibitors of histone deacetylases. | 09-18-2014 |
20140255939 | NUCLEIC ACID-BASED LINKERS FOR DETECTING AND MEASURING INTERACTIONS - The invention provides compositions comprising nucleic acid complexes for use in monitoring binding interactions and in measuring association and/or dissociation kinetics with or without force, detecting analytes, screening aptamers, and encoding/encrypting information. In some instances, the nucleic acid complexes are double-stranded nicked nucleic acids comprising a scaffold nucleic acid hybridized to one or more oligonucleotides. In some instances, a first and/or a second oligonucleotide are linked to moieties that are known to interact with each other or which are suspected of interacting with each other. | 09-11-2014 |
20140248311 | N-TERMINAL DELETED GP120 IMMUNOGENS - The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same. | 09-04-2014 |
20140243378 | Compositions and Methods for the Treatment of Muscular Disease, and Related Screening Methods - Disclosed are methods of treating a muscle disease and improving normal muscle function by administering a therapeutically effective amount of an isoprenoid antibiotic. Also disclosed are methods of upregulating hnRNP L and hnRNP L targets by administering a therapeutically effective amount of an isoprenoid antibiotic. Methods of screening compounds for use in treating muscle disease and improving muscle function are also described. | 08-28-2014 |
20140242616 | FREE NGAL AS A BIOMARKER FOR CANCER - Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer. | 08-28-2014 |
20140234938 | HARMONIC GENERATION FOR ACTIVATION OF SPECIES AND/OR DELIVERY OF SPECIES TO A TARGET ENVIRONMENT - Systems and methods for the activation of species and/or the delivery of species to a target environment using harmonic generation materials are generally described. | 08-21-2014 |
20140234847 | HIGH THROUGHPUT GENOME-WIDE TRANSLOCATION SEQUENCING - Provided are methods for high-throughput screening to determine locations of double-stranded DNA breaks (DSBs) and translocations in genomes caused by different agents, such as enzymes. | 08-21-2014 |
20140220617 | DIALYSIS LIKE THERAPEUTIC (DLT) DEVICE - A dialysis like therapeutic (DLT) device is provided. The DLT device includes at least one source channel connected at least one collection channels by one or more transfer channels. Fluid contacting surface of the channels can be an anti-fouling surface such as slippery liquid-infused porous surface (SLIPS). Fluids can be flown at high flow rates through the channels. The target components of the source fluid can be magnetic or bound to magnetic particles using an affinity molecule. A source fluid containing magnetically bound target components can be pumped through the source channel of the microfluidic device. A magnetic field gradient can be applied to the source fluid in the source channel causing the magnetically bound target components to migrate through the transfer channel into the collection channel. The collection channel can include a collection fluid to flush the target components out of the collection channel. The target components can be subsequently analyzed for detection and diagnosis. The source channel and the collection channels of the microfluidic device are analogous to the splenic arterioles and venules, respectively; the transfer channels mimic the vascular sinusoids of the spleen where opsonized particles are retained. Thus, the device acts as a dialysis like therapeutic device by combining fluidics and magnetics. | 08-07-2014 |
20140220004 | COMPOSITIONS AND METHODS FOR TREATING PAIN - Provided herein are compositions containing an antibody or antigen-binding antibody fragment that specifically binds to metallothionein 2 (MT2) protein, and compositions containing an agent that binds to or neutralizes a function of MT2 protein and/or an oligonucleotide that decreases the expression of MT2 mRNA in a mammalian cell, and optionally, one or more anti-inflammatory agents and/or analgesics. Also provided are methods of decreasing pain in a mammal that include administering to the mammal an agent that binds to or neutralizes a function of MT2 protein and/or an oligonucleotide that decreases the expression of MT2 mRNA in a mammalian cell, in an amount sufficient to decrease the level of extracellular MT2 protein or neutralize a function of extracellular MT2 protein in the mammal, thereby decreasing pain in the mammal. | 08-07-2014 |
20140219964 | METHODS FOR INDUCING CARDIOMYOCYTE PROLIFERATION - Methods for inducing cardiomyocyte proliferation, e.g., in vivo, by administering a composition comprising miRNA17-92 cluster oligonucleotides, e.g., miR-19a oligonucleotides, miR-19b oligonucleotides, or both miR-19a and miR-19b oligonucleotides. | 08-07-2014 |
20140213609 | PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION - Survival of, or axon regeneration in a lesioned mature central nervous system (CNS) neuron is promoted by (a) contacting the neuron with a therapeutically effective amount of an exogenous activator of protein translation; and (b) detecting the resultant promotion of the survival of, or axon regeneration in the neuron. | 07-31-2014 |
20140212335 | MAGNETIC SEPARATION USING NANOPARTICLES - Nanoparticles as described herein are configured to bind to bacterial contaminants, such as Gram positive bacteria, Gram negative bacteria, and endotoxins. The nanoparticles include a core comprising a magnetic material; and a plurality of ligands attached to the core. The ligands include, for example, bis(dipicolylamine) (“DPA”) coordinated with a metal ion, e.g., Zn | 07-31-2014 |
20140199781 | NON-INVASIVE METHODS FOR DIAGNOSING CHRONIC ORGAN TRANSPLANT REJECTION - Presented herein are methods of diagnosing or assessing an individual at increased risk of developing chronic rejection, or chronic allograft vasculopathy, based on analysis the individual's biomarker profile. | 07-17-2014 |
20140199329 | METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS - Embodiments of the technology described herein are based upon the discoveries that neturophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries. | 07-17-2014 |
20140194511 | DIETARY FORMULATIONS AND METHODS FOR TREATMENT OF INFLAMMATION AND OTHER DISORDERS - Dietary formulations in the form of an oil emulsion providing total enteral or parenteral nutrition, or in the form of food oil suitable for oral administration is provided. The formulations include about 2-60% by calories of a C | 07-10-2014 |
20140194358 | PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF - Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration. | 07-10-2014 |
20140193376 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT - The present embodiments provide for combinations of modulators that increase hematopoietic stem cell engraftment or increase mobilization in vivo. Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood are disclosed. One aspect of the invention relates to the use of a CXCR4 antagonist that act in concert with specific molar ratios of S1P receptor 1 (S1PR1) modulator agents to promote HSC mobilization. The invention also relates to methods of using these combinations of CXCR4 antagonists and S1PR1 modulator agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells, for example for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating a symptom associated with such diseases, disabilities or conditions. Another aspect of the invention relates to the use of a CXCR4 antagonist that act in concert with different, but specific molar ratios of S1P receptor 1 (S1PR1) modulator agents to promote HSC engraftment and methods for promoting HSC engraftment in a subject in need thereof, e.g., a recipient subject of a bone marrow or HSC transplant. Methods of screening for novel agents and pharmaceutical compositions comprising these agents are also disclosed. | 07-10-2014 |
20140186414 | METHODS AND USES FOR EX VIVO TISSUE CULTURE SYSTEMS - The technology described herein is directed to methods and devices that can be used to induce functional organ structures to form within an implantation device by implanting it in vivo within the body of a living animal, and allowing cells and tissues to impregnate the implantation device and establish normal microenvironmental architecture and tissue-tissue interfaces. Then the contained cells and tissues can be surgically removed intact and either transplanted into another animal or maintained ex vivo by perfusing it through one or more of the fluid channels with medium and/or gases necessary for cell survival. | 07-03-2014 |
20140179741 | USE OF CHELATORS OF DIVALENT CATIONS TO PROMOTE NERVE REGENERATION - Disclosed herein are methods to promote axonal outgrowth of a neuron comprising, contacting the neuron with an effective amount of a chelating agent, to thereby promote axonal outgrowth in the neuron. Also disclosed are methods of treating a subject for a CNS lesion, comprising, administering to the subject a therapeutically effective amount of a chelating agent, Also disclosed are devices for promoting regeneration in a lesioned neuron, and pharmaceutical compositions comprising a therapeutically effective amount of a chelating agent formulated for localized administration directly to an injured neuron. Examples of such chelating agents are provided. | 06-26-2014 |
20140178986 | SOLUBLE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF - The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF | 06-26-2014 |
20140161861 | Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries - Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury. | 06-12-2014 |
20140161791 | DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS OF KAWASAKI DISEASE - The present invention provides for compositions and methods for diagnosing and treating Kawasaki disease. More specifically, the proteomes of patients with KD are enriched for the meprin A, filamin B, and filamin C, which serve as biomarkers (and potential therapeutic targets) for KD. Accordingly, detection of these biomarkers, using compositions and methods provided for herein, can inform the therapy delivered to the subject. | 06-12-2014 |
20140154287 | MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION, AND METHODS AND USES THEREOF - The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time. | 06-05-2014 |
20140154286 | MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS - The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from | 06-05-2014 |
20140147880 | ORGAN MIMIC DEVICE WITH MICROCHANNELS AND METHODS OF USE AND MANUFACTURING THEREOF - System and method includes a body having a central microchannel separated by one or more porous membranes. The membranes are configured to divide the central microchannel into a two or more parallel central microchannels, wherein one or more first fluids are applied through the first central microchannel and one or more second fluids are applied through the second or more central microchannels. The surfaces of each porous membrane can be coated with cell adhesive molecules to support the attachment of cells and promote their organization into tissues on the upper and lower surface of the membrane. The pores may be large enough to only permit exchange of gases and small chemicals, or to permit migration and transchannel passage of large proteins and whole living cells. Fluid pressure, flow and channel geometry also may be varied to apply a desired mechanical force to one or both tissue layers. | 05-29-2014 |
20140142024 | BPI AND ITS CONGENERS AS RADIATION MITIGATORS AND RADIATION PROTECTORS - Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy. | 05-22-2014 |
20140135640 | AUTOMATED INTERPRETIVE MEDICAL CARE SYSTEM AND METHODOLOGY - Improved apparatus and methods for monitoring, diagnosing and treating at least one medical respiratory condition of a patient are provided, including a medical data input interface adapted to provide at least one medical parameter relating at least to the respiration of the patient, and a medical parameter interpretation functionality ( | 05-15-2014 |
20140134249 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 05-15-2014 |
20140112936 | METHODS OF NEUTRALIZING VIRAL INFECTION - Isolated, antigenic polypeptides including a pre-hairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a pre-hairpin intermediate conformation of gp41 and methods of making antibodies a that bind to pre-hairpin intermediate conformation of gp41 are also provided. Vaccines against a pre-hairpin Fd intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, pre-hairpin intermediate conformation of gp41 are further provided. | 04-24-2014 |
20140106378 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS - The present invention is based on the discovery that three proteins, Cystatin B, Chaperonin 10, and Profilin are present in the urine of patients with bladder cancer, a cancer of epithelial origin. Accordingly, the present invention is directed to methods for prognostic evaluation of cancers of epithelial origin and to methods for facilitating diagnosis of cancers of epithelial origin by monitoring the presence of these markers in biological samples. The invention is also directed to markers for therapeutic efficacy. | 04-17-2014 |
20140105960 | HYDROGELS FOR TISSUE REGENERATION - Provided herein are hydrogels and hydrogel-forming compositions that are useful for, among others, tissue regeneration in vivo. Methods for generating such hydrogels, for example, from such hydrogel-forming compositions are also provided herein. Therapeutic methods employing hydrogels and hydrogel-forming composition, for example, for restoration of tissue perfusion in the context of acute ischemia, are also provided. The disclosure also describes kits comprising components useful for generating hydrogels as described herein. | 04-17-2014 |
20140100377 | NOVEL FLUORINE-18 LABELED RHODAMINE DERIVATIVES FOR IMAGING WITH POSITRON EMISSION TOMOGRAPHY - The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents. | 04-10-2014 |
20140093906 | ORGAN MIMIC DEVICE WITH MICROCHANNELS AND METHODS OF USE AND MANUFACTURING THEREOF - System and method includes a body having a central microchannel separated by one or more porous membranes. The membranes are configured to divide the central microchannel into a two or more parallel central microchannels, wherein one or more first fluids are applied through the first central microchannel and one or more second fluids are applied through the second or more central microchannels. The surfaces of each porous membrane can be coated with cell adhesive molecules to support the attachment of cells and promote their organization into tissues on the upper and lower surface of the membrane. The pores may be large enough to only permit exchange of gases and small chemicals, or to permit migration and transchannel passage of large proteins and whole living cells. Fluid pressure, flow and channel geometry also may be varied to apply a desired mechanical force to one or both tissue layers. | 04-03-2014 |
20140093905 | ORGAN MIMIC DEVICE WITH MICROCHANNELS AND METHODS OF USE AND MANUFACTURING THEREOF - System and method includes a body having a central microchannel separated by one or more porous membranes. The membranes are configured to divide the central microchannel into a two or more parallel central microchannels, wherein one or more first fluids are applied through the first central microchannel and one or more second fluids are applied through the second or more central microchannels. The surfaces of each porous membrane can be coated with cell adhesive molecules to support the attachment of cells and promote their organization into tissues on the upper and lower surface of the membrane. The pores may be large enough to only permit exchange of gases and small chemicals, or to permit migration and transchannel passage of large proteins and whole living cells. Fluid pressure, flow and channel geometry also may be varied to apply a desired mechanical force to one or both tissue layers. | 04-03-2014 |
20140074253 | SCAFFOLDS COMPRISING NANOELECTRONIC COMPONENTS FOR CELLS, TISSUES, AND OTHER APPLICATIONS - The present invention generally relates to nanoscale wires and tissue engineering. In various embodiments, cell scaffolds for growing cells or tissues can be formed that include nanoscale wires that can be connected to electronic circuits extending externally of the cell scaffold. The nanoscale wires may form an integral part of cells or tissues grown from the cell scaffold, and can even be determined or controlled, e.g., using various electronic circuits. This approach allows for the creation of fundamentally new types of functionalized cells and tissues, due to the high degree of electronic control offered by the nanoscale wires and electronic circuits. Accordingly, such cell scaffolds can be used to grow cells or tissues which can be determined and/or controlled at very high resolutions, due to the presence of the nanoscale wires, and such cell scaffolds will find use in a wide variety of novel applications, including applications in tissue engineering, prosthetics, pacemakers, implants, or the like. | 03-13-2014 |
20140058069 | PARTICLES AND OTHER SUBSTRATES USEFUL IN PROTEIN PURIFICATION AND OTHER APPLICATIONS - The present invention generally relates to particles, including microgel particles, for purifying proteins and other species. In one aspect, the particles comprise a metal-chelating moiety, which may be distributed substantially evenly throughout the particle in certain embodiments. In some cases, the particles may be porous, and in some embodiments, the particles may be made sufficiently small, for example, in order to form a microgel containing the particles. Such particles may be useful, for example, in binding metal ions (for example, nickel ions) using the metal-chelating moieties. In some embodiments, such particles may also be used to bind certain analytes (for example, proteins) containing tags which attract metal ions, for example, histidine tags. Accordingly, in certain embodiments, the particles may be used for binding or trapping proteins. In some cases, this process is reversible; for example, upon exposure of the particles to a histidine competitor, proteins or other analytes containing the histidine tags may be released form the particles. Other aspects of the invention are generally directed to methods of using such particles, methods of forming such particles, kits including such particles, or the like. | 02-27-2014 |
20140056872 | ANTAGONISTS OF NEUROPILIN RECEPTOR FUNCTION AND USE THEREOF - The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases. | 02-27-2014 |
20140044684 | Methods And Compositions For Regulating Gene Expression - In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translation termination. | 02-13-2014 |
20140031383 | METHODS FOR TREATMENT OF MELANOMA - The present invention is directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods herein are directed to screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma. | 01-30-2014 |
20140010848 | GAS-FILLED MICROBUBBLES AND SYSTEMS FOR GAS DELIVERY - Compressible and concentrated suspensions containing gas-filled microbubbles, uses thereof for delivering gas into a subject in need thereof, and systems for delivering the compressible suspensions. The gas-filled microbubbles each comprise a gas core surrounded by a lipid membrane, which includes (a) one or more lipids, such as 1,2-disteroyl-sn-glycero-3-phosphocholine (DSPC) or dipalmitoylphosphatidylcholine (DPPC), and (b) one or more stabilizing detergents, such as poloxamer 188, Pluronic F108, Pluronic F127, polyoxyethylene (100) stearyl ether, cholesterol, gelatin, polyvinylpyrrolidone (PVP), and sodium deoxycholate (NaDoc). | 01-09-2014 |
20130338424 | TRANSCRANIAL MAGNETIC STIMULATION (TMS) METHODS AND APPARATUS - Method and devices are provided for treating subjects with Transcranial Magnetic Stimulation (TMS). According to some approaches, the methods and devices are configured for the treatment of ongoing seizures. Other approaches relate to the use of TMS as an antiepileptogenic or for use in determining preferential placement of intracranial probes. | 12-19-2013 |
20130338243 | METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals. | 12-19-2013 |
20130324946 | IMPLANTABLE DRUG DELIVERY DEVICE AND METHODS - A method is provided for local controlled delivery of a drug to the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens of a patient in need of treatment. In one embodiment, the method includes implanting a resorbable drug delivery device within the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens of the patient. The drug delivery device may include an elastic device body housing at least one drug reservoir which contains at least one drug. In a preferred embodiment, the method further includes releasing the drug from the device in a controlled manner to, typically directly to, the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens. | 12-05-2013 |
20130315880 | ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS - The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. | 11-28-2013 |
20130304230 | BLADDER RECONSTRUCTION - The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of the luminal organ or tissue structure with a first cell population on or in a first area and a second cell population such as a smooth muscle cell population in a second area of the polymeric matrix. The method involves grafting the device to an area in a patient in need of treatment. The polymeric matrix comprises a biocompatible and biodegradable material. | 11-14-2013 |
20130289687 | Nanowired Three Dimensional Tissue Scaffolds - Electrically conductive nanowires incorporated within scaffolds enhance tissue growth, bridge the electrically resistant pore walls and markedly improve electrical communication between adjacent cardiac cell bundles. Integration of conducting nanowires within 3D scaffolds should improve the therapeutic value of cardiac patches. Examples demonstrate efficacy of gold nanowires in alginate matrices seeded with cardiomyocytes. | 10-31-2013 |
20130288993 | METHOD FOR DIAGNOSIS AND METHOD OF TREATMENT OF AUTISM SPECTRUM DISORDERS AND INTELLECTUAL DISABILITY - We provide a set of novel mutations in HIST3H3, AMT, GLDC and PEX7 genes which we have discovered as causative of some autism spectrum disorders and/or intellectual disability after analysis of families with more than one affected child and with consanguineous parents. Based on some of these mutations, we also provide novel treatment options for autism spectrum disorders and/or intellectual disability wherein the novel mutations have been diagnosed. The invention is based on the discovery that certain specific mutations, particularly when present in a homozygous, compound heterozygous, or trans heterozygous combinations, result in a phenotype of an autism spectrum disorder and/or intellectual disability. Some mutations also cause the disorder or disease as heterozygous mutation. | 10-31-2013 |
20130281312 | METHODS FOR PREDICTING ANTI-CANCER RESPONSE - The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs. | 10-24-2013 |
20130274874 | CURVED FIBER ARRANGEMENT FOR PROSTHETIC HEART VALVES - A leaflet including fibers oriented at an angle relative to at least one free edge of the leaflet. A leaflet comprising mechanisms for increasing coaptation height, preventing billowing, and reducing stress in critical regions of the leaflet. A prosthetic heart valve, including three leaflets operatively attached together. A method of using a prosthetic heart valve, by applying pressure to the valve, forming a pocket with material of three leaflets operatively attached together and increasing coaptation height, reducing billowing of the leaflets toward a ventricle, and reducing stress in critical regions of the leaflet. A chorded valve including at least one leaflet, wherein bundles of fibers exit said free edges as tethers and can be anchored to tissue. A method of using the chorded valve, by anchoring the tethers to tissue, forming a pocket with the material of leaflets and increasing coaptation height, and reducing billowing of leaflets toward an atrium. | 10-17-2013 |
20130245130 | NATURAL PRODUCT ANTIBIOTICS AND ANALOGS THEREOF - Provided herein are pure and isolated natural products and analogs thereof of Formula (I), (II), (III), and (IV), pharmaceutical compositions thereof, and methods of use, for example, for treating a bacterial infection. Further provided are methods useful in identifying an inhibitor of bacterial sugar fermentation in a bacterial strain, such as a compound (inhibitor) of Formula (I), (II), (III), or (IV): | 09-19-2013 |
20130236977 | COMPOSITIONS AND METHODS FOR PLASMA PEPTIDE ANALYSIS - Provided herein are composition, methods and kits for peptide analysis in blood by mass spectroscopy. Isotopic peptides are also provided that facilitate quantification of peptide levels, e.g., hepcidin levels, in blood by mass spectroscopy. Further disclosed are methods and compositions for quantifying blood hepcidin levels and evaluating iron-associated disorders. | 09-12-2013 |
20130236429 | ENGINEERED VASCULAR ADIPOSE TISSUE - Embodiments of the invention relate to methods, compositions and kits for the in vivo formation of vascularized new adipose tissue in a subject. Combination of endothelial progenitor cells (EPCs) and mesenchymal progenitor cells (MPCs) implanted in vivo in a subject work synergistically to promote the formation vascularized new adipose tissue. | 09-12-2013 |
20130231609 | DEVICE FOR MIXING AND DELIVERING FLUIDS FOR TISSUE REPAIR - A device for mixing and delivering a mixture of fluids to a target site includes a tube for containing the mixture. A compressible auger for mixing the fluids is movably disposed within the tube, one end of the auger being free at the distal end of the tube. A plunger is also movable within the tube in communication with the other end of the auger. When the plunger is moved axially within the tube the auger also moves axially and the auger is compressed to dispense the fluid. The mixing and delivery device can be used with an apparatus for the arthroscopic delivery of a tissue repair material to a repair site. The apparatus includes a first sheath and a second sheath removably attached to the first sheath for delivering the tissue repair material to the repair site. | 09-05-2013 |
20130230504 | PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND METHODS OF USE THEREOF - The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity. | 09-05-2013 |
20130216507 | METHODS FOR PROMOTING HSC ENGRAFTMENT - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 08-22-2013 |
20130209424 | COMPOSITIONS FOR PROMOTING HEMATOPOIETIC STEM CELL GROWTH - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 08-15-2013 |
20130209423 | METHODS FOR PROMOTING HEMATOPOIETIC RECONSTITUTION - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 08-15-2013 |
20130190726 | MOTION COMPENSATING CATHETER DEVICE - A catheter system allows for percutaneous intervention on the fast-moving structures inside the heart. The device consists of a steerable catheter sheath, an actuated, multi-degree of freedom moving catheter, and a catheter end effector, such as a fixation device. An actuator controls the motion of the catheter guide-wire in the catheter sheath to follow the motion of the target tissue. A control system controls the actuator and compensates for mechanical characteristics of the system including friction and backlash. A 3-D imaging system can be used to view the motion of the target tissue and the catheter end effector and produce 3-D imaging data. The 3-D imaging data can be used by the control system to track the target tissue and accurately position the end effector with respect to the moving target tissue allowing a clinician to repair the target tissue while it is moving. The system can be used to perform mitral valve annuloplasty wherein the actuated catheter compensates for the heart valve motion and an end effector fixation device is used to place fixation items, like anchors or staples, into the heart valve tissue to fix the annulus. | 07-25-2013 |
20130189783 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 - The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via β1 integrin activation. | 07-25-2013 |
20130178731 | METHODS AND APPARATUS FOR RISK ASSESSMENT OF DEVELOPMENTAL DISORDERS DURING EARLY COGNITIVE DEVELOPMENT - The nonlinear complexity of EEG signals is believed to reflect the scale-free architecture of the neural networks in the brain. Analysis of the complexity and synchronization of EEG signals as described herein provides a quantitative measure for routine monitoring of functional brain development in infants and young children and provide a useful biomarker for detecting functional abnormalities in the brain before the cognitive, behavioral or social manifestations of these brain developments can be observed and measured by standard tests. One or more machine learning algorithms are used to discover relevant patterns in the complexity and synchronization values determined from the EEG data to facilitate risk assessment and/or diagnosis of developmental disorders in infants and young children by predicting cognitive, behavioral and social outcomes of the measured functional brain activity patterns. | 07-11-2013 |
20130177912 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS - The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation. | 07-11-2013 |
20130150432 | EFFICACY OF CANCER THERAPY - Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors. | 06-13-2013 |
20130129629 | MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES - The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies. | 05-23-2013 |
20130123228 | PROMOTING AXON REGENERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION - Survival of, or axon regeneration in a lesioned mature central nervous system (CNS) neuron is promoted by (a) contacting the neuron with a therapeutically effective amount of an exogenous activator of protein translation; and (b) detecting the resultant promotion of the survival of, or axon regeneration in the neuron. | 05-16-2013 |
20130123124 | METHODS AND COMPOSITIONS FOR CHARACTERIZING AUTISM SPECTRUM DISORDER BASED ON GENE EXPRESSION PATTERNS - The invention relates to methods and kits for characterizing and diagnosing autism spectrum disorder in an individual based on gene expression levels. | 05-16-2013 |
20130101582 | Tiki1 and Tiki2, Wnt Inhibitors - This invention relates to Tiki1 and Tiki2 proteins and nucleic acids, cells expressing the same, and methods for identifying compounds that modulate Tiki1/2 activity for use in the treatment of osteoporosis or cellular proliferative disorders. | 04-25-2013 |
20130072425 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF - The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50 | 03-21-2013 |
20130045922 | PRO-ANGIOGENIC FRAGMENTS OF PROMININ-1 AND USES THEREOF - Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof. | 02-21-2013 |
20130039947 | NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF - The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection. | 02-14-2013 |
20130036983 | Method and System for Mass Production of Fish Embryos - A method and system for producing large quantities of aquatic animal embryos includes providing a water filled spawning tank adapted for holding the male and female aquatic animals in various configurations. The system can include a spawning platform which includes a porous or perforated element that allows the embryos but not the aquatic animal to pass through and a separator which includes a porous or perforated element that can be used to separate the male aquatic animals from the female aquatic animals during a priming phase. In operation, the spawning platform can be placed in the bottom of the tank in order to provide a bottom collection area where the embryos can be collected and the aquatic animals cannot eat or otherwise harm the embryos. The female aquatic animals can be placed in tank above the spawning platform. The separator can be placed in the tank above the female aquatic animals and the male aquatic animals can be placed in the tank above, remaining separated from the female aquatic animals, beginning the priming phase. When embryos are desired, the separator can be removed allowing the male aquatic animals to mingle with the female aquatic animals and the height of the water above the porous or perforated element of the spawning platform can be changed, by raising the spawning platform or lowering the water level, in the spawning phase. The porous or perforated element of the spawning platform can be undulating or angled with respect to horizontal to create areas of varying depth over the surface of the porous or perforated element of the spawning platform to improve embryo production. | 02-14-2013 |
20130029950 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE VASCULAR DISORDERS - The technology described herein is directed to methods and compositions for the treatment of proliferative vascular disorders, e.g. hemangioma. In some aspects, the methods and compositions described herein related to a mTOR inhibitor or nifedipine. | 01-31-2013 |
20130028959 | Liposomes for Preventing the Spread of HIV - Formulations for preventing the sexual transmission of the HIV virus are provided. In one embodiment, the formulations contain un-conjugated liposomes whose physicochemical properties allow binding to the HIV virus. The liposomes are made up of natural or synthetic lipids, alone or in combination. Preferably, the liposomes are made entirely of cardiolipin. In other embodiments the liposomes are modified to contain Hgands which bind HIV. The method for preventing the sexual transmission of the HIV virus includes self-administration of a formulation containing an effective amount of liposomes which bind to the HIV virus to the surface of a mucosal membrane prior to intercourse. | 01-31-2013 |
20130028885 | METHODS TO PREDICT AND PREVENT RESISTANCE TO TAXOID COMPOUNDS - Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided. | 01-31-2013 |
20130028516 | IMAGE REGISTRATION METHODS AND APPARATUS USING RANDOM PROJECTIONS - According to some aspects, a computer-implemented method of registering a first image and a second image is provided. The method comprises computer-implemented acts of logically dividing the first image into a first plurality of regions, logically dividing the second image into a second plurality of regions, projecting the first plurality of regions and the second plurality of regions into a lower dimensional space using random projections, determining, for each of the projected first plurality of regions, at least one of the projected second plurality of regions that is closest according to first criteria, and determining a transform that brings each of the projected first plurality of regions into a closest correspondence with the respective at least one of the projected second plurality of regions according to second criteria, the transform indicating the registration of the first image and the second image. According to some aspects, at least one computer readable medium encoding instructions that when executed perform such a method and/or a system for providing such a method is provided. | 01-31-2013 |
20120315283 | METHODS OF PROMOTING TISSUE GROWTH AND TISSUE REGENERATION - Described herein are methods of using soluble epoxide hydrolase inhibitors to modulate the levels of epoxyeicosatrienoic acids (EETs) in order to increase angiogenesis and promote wound healing and tissue regeneration. | 12-13-2012 |
20120283831 | METHODS AND PROCEDURES FOR LIGAMENT REPAIR - Methods and devices for the repair of a ruptured ligament using a scaffold device are provided. Aspects of the invention, may include a scaffold attached by a suture to an anchor. In aspects of the invention, the anchor may be secured to a bone near or at the repair site. | 11-08-2012 |
20120270236 | VOLTAGE-GATED PROTON CHANNEL, Hv1, AND USES THEREFOR - Nucleic acid and protein sequences relating to a proton channel (HvI) are disclosed. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the HvI gene and protein are disclosed. Also provided are methods of identifying modulators of HvI activity, methods of geno typing subjects with respect to HvI, and methods of diagnosing and treating HvI-mediated disorders. | 10-25-2012 |
20120252727 | MUCOSAL DELIVERY OF THERAPEUTIC MOLECULES, PROTEINS, OR PARTICLES COUPLED TO CERAMIDE LIPIDS - Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER). | 10-04-2012 |
20120251577 | SELECTIVELY DISRUPTED WHOLE-CELL VACCINE - The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell | 10-04-2012 |
20120238914 | ACTIVELY CONTROLLED ORTHOTIC DEVICES - An actively controlled orthotic device includes active components that dynamically change the structural characteristics of the orthotic device according to the orientation and locomotion of the corresponding body part, or according to the changing needs of the subject over a period of use. Accordingly, the orthotic device can be effectively employed to provide locomotion assistance, gait rehabilitation, and gait training. Similarly, the orthotic device may be applied to the wrist, elbow, torso, or any other body part. The active components may be actuated to effectively transmit force to a body part, such as a limb, to assist with movement when desired. Additionally or alternatively, the active components may also be actuated to provide support of varying rigidity for the corresponding body part. | 09-20-2012 |
20120238460 | RANTES LEVELS AS A DIAGNOSTIC AND THERAPEUTIC FOR ACUTE GRAFT VERSUS HOST DISEASE - Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for donor plasma concentration of RANTES in a sample obtained from a donor of the hemtopoietic stem cells, and comparing the donor plasma concentration of RANTES to a predetermined level, wherein a donor plasma concentration of RANTES less than the predetermined level indicates a likelihood of the subject to develop aGVHD upon receiving myeloablative allogeneic HSCT from that donor. Other methods include assaying for day 0, or for day 7, plasma concentration of MCP-1 in a sample obtained from the subject, and comparing the day 0 or day 7, plasma concentration of MCP-1 to a predetermined level. | 09-20-2012 |
20120201896 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 08-09-2012 |
20120195862 | BIOMECHANICAL INDUCTION OF HEMATOPOIESIS - The present invention provides methods and compositions for increasing the hematopoietic potential of a population of hematopoietic progenitor cells, vascular cells, and or hemogenic endothelium, by exposing the cells to at least one external biomechanical stimulus. More specifically, the application of shear stress to hematopoietic progenitor cells or endothelial cells stimulates hematopoiesis, with or without concurrent application of other extrinsic modulators of hematopoiesis. | 08-02-2012 |
20120190659 | ANGIOGENESIS INHIBITORS - Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis: | 07-26-2012 |
20120189594 | METHODS FOR PROMOTING HSC SELF-RENEWAL - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 07-26-2012 |
20120189593 | METHODS FOR PROMOTING HSC ENGRAFTMENT - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 07-26-2012 |
20120189592 | METHODS FOR PROMOTING HEMATOPOIETIC RECONSTITUTION - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 07-26-2012 |
20120149021 | Device for Filtration of Fluids Therethrough and Accompanying Method - A microfluidic device for separating target components from a source fluid includes one or more source channels connected to one or more collection channels by one or more transfer channels. The target components of the source fluid can be magnetic or bound to magnetic particles using a know binding agent. A source fluid containing magnetically bound target components can be pumped through the source channel of the microfluidic device. A magnetic field gradient can be applied to the source fluid in the source channel causing the magnetically bound target components to migrate through the transfer channel into the collection channel. The collection channel can include a collection fluid that is stagnant until a predefined volume of source fluid is processed or a predefined volume of target components accumulate in the collection channel, at which point collection fluid can be pumped into the collection channel to flush the target components out of the collection channel. The target components can be subsequently analyzed for detection and diagnosis. | 06-14-2012 |
20120128715 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS - The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific). | 05-24-2012 |
20120121557 | NEUREGULIN INDUCED PROLIFERATION OF CARDIOMYOCYTES - The present invention provides methods for inducing division of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to repair heart tissue damaged by, for example, myocardial ischemia, hypoxia, stroke, myocardial infarction or chronic ischemic heart disease in vivo. In addition, the methods of the invention can be used to induce heart muscle cells to divide in vitro, in vivo and/or ex vivo, which can then be used in heart tissue repair. | 05-17-2012 |
20120121552 | METHODS FOR PURIFYING HEMATOPOIETIC STEM CELLS - Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells. | 05-17-2012 |
20120115134 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER - We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested. | 05-10-2012 |
20120114668 | METHOD FOR MODULATING ANGIOGENESIS USING FIBROMODULIN - Described herein are compositions and uses thereof to inhibit or enhance the activity of fibromodulin (FMOD). Such compositions are useful in methods for treatment of age-related macular degeneration involving choroid neovascularization in a subject comprising administering a therapeutically effective amount of a fibromodulin activity inhibitor to the subject. | 05-10-2012 |
20120107403 | BLADDER RECONSTRUCTION - The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of the luminal organ or tissue structure with a first cell population on or in a first area and a second cell population such as a smooth muscle cell population in a second area of the polymeric matrix. The method involves grafting the device to an area in a patient in need of treatment. The polymeric matrix comprises a biocompatible and biodegradable material. | 05-03-2012 |
20120101067 | METHODS FOR ENHANCING HEMATOPOIETIC PROGENITOR CELL ENGRAFTMENT - Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation. | 04-26-2012 |
20120083689 | LIGHT-GUIDED TRANSLUMINAL CATHETER - Generally, the present invention is directed to a light-guided catheter for direct visualization of placement through the skin. An embodiment of the invention includes a method for transcutaneous viewing and guiding of intracorporeal catheters into a body that comprises inserting a catheter into the body having at least one lumen and internally illuminating the catheter with light capable of propagating through the blood and tissue to an external viewer outside of the body. | 04-05-2012 |
20120058099 | USE OF HYPOXANTHINE FOR PROMOTION OF NEURONAL OUTGROWTH - Disclosed herein is a method of promoting neuronal outgrowth in a neuron. The method comprises contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth of the neuron. The hypoxanthine may be contacted in the absence of xanthine oxidase and/or in the absence of exogenous nerve growth factor (NGF), and/or in the absence of exogenous D-mannose, and/or in the absence of exogenous oncomodulin, and/or in the absence of exogenous TGF-B. The neuron may be an optic nerve neuron or a retinal neuron and/or an injured neuron. Neurons may be from the central nervous system (CNS) or the peripheral nervous system (PNS). The methods are useful for treating an injured neuron, for example to an optic nerve neuron, resulting from branch and central vein/artery occlusion, trauma, edema, angle-closure glaucoma, open-angle glaucoma. Methods of treatment of various neurological injuries and diseases, as well as therapeutic compositions, are also disclosed. | 03-08-2012 |
20120045472 | Biochemically Stabilized HIV-1 ENV Trimer Vaccine - Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. | 02-23-2012 |
20120028268 | METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals. | 02-02-2012 |
20120020953 | DIAGNOSIS AND TREATMENT OF CANCER - Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof. | 01-26-2012 |
20110306555 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 12-15-2011 |
20110305676 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 12-15-2011 |
20110300154 | TREATMENT OF AIRWAY HYPERREACTIVITY - The invention provides strategies for treating and preventing airway hyperreactivity and non-allergic asthma comprising antagonizing IL-17 activity and/or production by iNKT cells. Provided herein is a method of diagnosing non-allergic asthma and airway hyperreactivity comprising neutrophils quantification in sputum. | 12-08-2011 |
20110293582 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 12-01-2011 |
20110281759 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 11-17-2011 |
20110268736 | METHOD FOR TREATING CONGENITAL MYOPATHY - The invention relates to methods and compositions for therapy for congenital myopathies. | 11-03-2011 |
20110256526 | DETECTION OF HUMAN SOMATIC CELL REPROGRAMMING - The methods and kits described herein are based, in part, to the discovery phenotype representing a fully-reprogrammed iPS cell and several reprogramming intermediates. The methods and kits described herein permit identification of fully-reprogrammed iPS cells and further permits one of skill in the art to monitor the emergence of iPS cells during the reprogramming process. The methods/kits can also be performed using real time using live cell imaging. Also described herein are methods for screening candidate reprogramming agents by monitoring the emergence of fully-reprogrammed iPS cells in the presence and absence of such an agent. | 10-20-2011 |
20110250585 | ORGAN MIMIC DEVICE WITH MICROCHANNELS AND METHODS OF USE AND MANUFACTURING THEREOF - System and method includes a body having a central microchannel separated by one or more porous membranes. The membranes are configured to divide the central microchannel into a two or more parallel central microchannels, wherein one or more first fluids are applied through the first central microchannel and one or more second fluids are applied through the second or more central microchannels. The surfaces of each porous membrane can be coated with cell adhesive molecules to support the attachment of cells and promote their organization into tissues on the upper and lower surface of the membrane. The pores may be large enough to only permit exchange of gases and small chemicals, or to permit migration and transchannel passage of large proteins and whole living cells. Fluid pressure, flow and channel geometry also may be varied to apply a desired mechanical force to one or both tissue layers. | 10-13-2011 |
20110230568 | HEATING OF POLYMERS AND OTHER MATERIALS USING RADIATION FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to systems and methods for releasing a releasable species from an article using an external trigger, for example, using infrared or near-infrared radiation. Such systems and methods may be useful, for example in biological applications (e.g., as an implant within a subject), industrial applications, commercial applications, or the like. One aspect of the invention is generally directed to an article containing a radiation-sensitive polymer or other radiation-sensitive material. Exposure of the radiation-sensitive material to radiation such as infrared or near-infrared radiation may cause the material to increase in temperature. This increase in temperature may be used, in some cases, to cause the release of a drug or other releasable species from the article. For instance, a drug may be contained in a heat-sensitive material positioned in thermal communication with the radiation-sensitive material, or a drug may be contained within an enclosure that is isolated, at least in part, by a heat-sensitive material positioned in thermal communication with the radiation-sensitive material. In another aspect of the invention, a receive antenna may be used to focus infrared or near- infrared radiation on an article. For instance, the receive antenna may focus infrared or near-infrared radiation on a radiation-sensitive material in the article. Such focusing may be useful, in some embodiments, to control release of a drug or other releasable species from the article. Other aspects of the invention are directed to systems and methods of making or using such articles, e.g., by implanting the article within a subject, methods of treatment involving such articles, kits including such articles, and the like. | 09-22-2011 |
20110212163 | MAGNETIC HEATING FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to systems and methods for releasing a compound from an article using an external trigger, for example, magnetic fields. One aspect of the invention is generally directed to an article containing a magnetically-susceptible material. Exposure of the magnetically-susceptible material to a magnetic field, such as an oscillating magnetic field, may cause the magnetically-susceptible material to increase in temperature. This increase in temperature may be used, in some embodiments, to cause the release of a drug or other releasable material from the article. For instance, the drug may be contained in a heat-sensitive material in thermal communication with the magnetically-susceptible material, or the drug may be contained within an enclosure that is isolated, at least in part, by a heat-sensitive material in thermal communication with the magnetically-susceptible material. Other aspects of the invention are directed to systems and methods of making or using such articles, e.g., by implanting the article within a subject, methods of treatment involving such articles, kits including such articles, or the like. | 09-01-2011 |
20110212027 | RADIATIVE HEATING FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to systems and methods for releasing a releasable species from an article using an external trigger, for example, using microwave radiation or other forms of radiation, e.g., radiofrequency radiation. Such systems and methods may be useful, for example, in biological applications (e.g., as an implant within a subject), industrial applications, commercial applications, or the like. One aspect of the invention is generally directed to an article containing a radiation-sensitive polymer or other radiation-sensitive material. Exposure of the radiation- sensitive material to radiation such as microwave and/or radiofrequency radiation may cause the material to increase in temperature. This increase in temperature may be used, in some cases, to cause the release of a drug or other releasable species from the article. For instance, a drug may be contained in a heat-sensitive material positioned in thermal communication with the radiation-sensitive material, or a drug may be contained within an enclosure that is isolated, at least in part, by a heat-sensitive material positioned in thermal communication with the radiation-sensitive material. In another aspect of the invention, a receive antenna, such as a microwave receive antenna may be used to focus microwave and/or radiofrequency radiation on an article. For instance, the receive antenna may focus microwave and/or radiofrequency radiation on a radiation-sensitive material in the article. Such focusing may be useful, in some embodiments, to control release of a drug or other releasable species from the article. Other aspects of the invention are directed to systems and methods of making or using such articles, e.g., by implanting the article within a subject, methods of treatment involving such articles, kits including such articles, and the like. | 09-01-2011 |
20110206716 | SYNERGISTIC IMMUNOGENIC FUSION PROTEIN-POLYSACCHARIDE CONJUGATE - An immunogenic composition comprising a fusion protein-polysaccharide conjugate consisting of a polysaccharide (PS) or pneumococcal bacterial cell wall polysaccharide (CWPS) conjugated to X:PdT where PdT represents the nonhemolytic variant of pneumolysin and X represents an antigenic peptide or protein of interest is provided. The immunity to X is synergistically enhanced by the fusion conjugate. Methods of protecting a subject from pneumococcal colonization or disease by administering an immunogenic composition including a fusion protein (PsaA:PdT) containing truncated PsaA and the nonhemolytic variant of pneumolysin (PdT) conjugated with CWPS (PsaA:PdT-CWPS) is also provided. | 08-25-2011 |
20110190210 | PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF - Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration. | 08-04-2011 |
20110183899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY - The invention relates to methods and compositions for the treatment of obesity. The methods and compositions relate to the use of an agent that reduces or prevents endoplasmic reticulum stress in conjunction with leptin. | 07-28-2011 |
20110182867 | MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES - The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies. | 07-28-2011 |
20110166060 | TYMPANIC MEMBRANE PERMEATING EAR DROPS AND USES THEREOF - The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration enhancer which increases the flux of a therapeutic agent (e.g., antibiotic) across the tympanic membrane. Such compositions are particularly useful in the treatment of otitis media. Additionally, the composition may include a sustained release agents that, in some embodiments form sustained release reservoirs, in situ, once administered to a patient. | 07-07-2011 |
20110159040 | NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF - An aspect of the present invention provides for methods for identifying novel immunogens that when administered as vaccines elicit a cellular or humoral immunogenic response. In a particular embodiment, a method identified pneumococcal T-cell immunogens that elicit systemic IL-17A responses, and reduce or protect against pneumococcal colonization. | 06-30-2011 |
20110151447 | METHOD TO PRODUCE INDUCED PLURIPOTENT STEM (IPS) CELLS FROM NON-EMBRYONIC HUMAN CELLS - The invention provides methods for generating induced pluripotent stem (iPS) cells from normal and mutant adult cells, as well as the iPS cells so generated from such methods. In some aspects, iPS cells are generated by ectopically expressing SOX2 and OCT4 nucleic acids in such adult cells. Other nucleic acids such as but not limited to MYC may also be ectopically expressed in such adult cells in the methods described herein. | 06-23-2011 |
20110150894 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 - The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via β1 integrin activation. | 06-23-2011 |
20110104725 | Method of Effecting Coagulation in a Droplet - The invention provides techniques for coagulating blood on a droplet actuator. The invention also provides methods of manipulating the coagulated blood including a variety of droplet operations that may be conducted using the coagulated blood. Further, the invention provides a variety of assays that make use of the coagulated blood or various blood samples as input. | 05-05-2011 |
20110086922 | SENSORY-SPECIFIC LOCAL ANESTHESIA AND PROLONGED DURATION LOCAL ANESTHESIA - Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block over motor block. The duration of block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is provided by selecting the concentration of the local anesthetic and the permeation enhancer to provide selective permeability of the sensory and motor neurons to the enhancer. | 04-14-2011 |
20110086041 | Fusion-Intermediate State of HIV-1 gP41 Targeted by Broadly Neutralizing Antibodies - Isolated, antigenic polypeptides including a prehairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a prehairpin intermediate conformation of gp41 and methods of making antibodies a that bind to prehairpin intermediate conformation of gp41 are also provided. Vaccines against a prehairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, prehairpin intermediate conformation of gp41 are further provided. | 04-14-2011 |
20110071088 | METHOD FOR TREATING NEUROLOGICAL DISORDERS - The present invention is based on the discovery that suppressing the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration unless the intrinsic growth program of neurons is also activated. Accordingly, the present invention is directed to methods of stimulating axon regeneration using a combination therapy wherein agents that inhibit NgR activity or downstream pathways activated by inhibitory signals are combined with agents that activate the growth pathway of neurons (e.g. polypeptide growth factors, activators of macrophages, purine nucleosides, or hexoses). | 03-24-2011 |
20110061120 | SELF-CLEAVING RIBOZYMES AND USES THEREOF - In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs. | 03-10-2011 |
20110059152 | AUGMENTATION OF ORGAN FUNCTION - The present invention provides methods and compositions for augmenting organ functions using small-scale matrix implants generated by seeding tissue-specific or undifferentiated cells onto a matrix materials (e.g., a wafer, sponge, or hydrogel). The seeded matrix composition can then be implanted and will develop into an organ-supplementing structure in vivo. Continued growth and differentiation of the seeded cells on the implanted matrix results in the formation of a primitive vascular system in the tissue. The primitive vascular system can then develop into a mature vascular system, and can also support the growth and development of additional cultured cell populations. The seeded matrix system can be used to introduce a variety of different cells and tissues in vivo. | 03-10-2011 |
20110054306 | TISSUE CLIP - A tissue clip for adjoining tissues including a body portion, a biasing mechanism interconnecting the body portion to a tissue grasping mechanism, the grasping mechanism having a first condition wherein the grasping mechanism is extending against and away from the body portion and a second condition wherein the grasping mechanism is biased against the body portion. A tissue clip and deployer combination. A method of interconnecting tissue by deploying the tissue clip, puncturing tissue to be interconnected with the tissue clip, and interconnecting the tissue. A method of treating an aneurism by deploying the tissue clip at an aneurism site, closing off the aneurism site with the tissue clip, and treating the aneurism. A method of imaging a surgical procedure with ultrasound by modifying a surface of a metal surgical instrument, and imaging the metal surgical instrument with ultrasound during a surgical procedure. | 03-03-2011 |
20110052570 | METHOD TO PROGNOSE RESPONSE TO ANTI-EGFR THERAPEUTICS - The present invention provides methods to determine the likelihood of effectiveness of an EGFR targeting treatment in a subject affected with a tumor based on the expression of EGFR of endothelial cells associated with the tumor. The present invention also provides methods of treating a subject affected with, or at risk for developing cancer with an EGFR targeting treatment and methods to screen for an EGFR targeting treatment. | 03-03-2011 |
20110028561 | PROTECTION OF NEURAL RETINA BY REDUCTION OF ROD METABOLISM - Described herein are methods for treatment or prevention of retinal dysfuntion by reduction of rod cell energy demand. Particular embodiments include methods for improving rod-mediated retinal function in a developing retina by administering an agent that reduces energy demand in the rod cell. Such agents that target rod cell energy demand can be administered to a subject at risk for retinal dysfunction to modify rod-cell function, such that the retina reaches retinal maturity. Also described herein are methods for suppressing the visual cycle in a developing rod cell by contacting the cell with an agent that reduces the energy demand of the rod cell. | 02-03-2011 |
20110027338 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 02-03-2011 |
20110020326 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASE - The present invention is directed toward methods for treating, inhibiting the progression of or eradicating polycystic kidney disease in a mammal in need thereof by providing a cMET inhibitor. | 01-27-2011 |
20110009370 | METHOD TO ENHANCE TISSUE REGENERATION - The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect. | 01-13-2011 |
20100278792 | METHOD OF ENHANCING PROLIFERATION AND/OR HEMATOPOIETIC DIFFERENTIATION OF STEM CELLS - The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. The method of the present invention comprises increasing the intracellular level of a cdx in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous cdx protein to the cell, or by introduction into the cell of a genetic construct encoding a cdx. The cdx is selected from the cdx family and includes cdx1, cdx2, or cdx4. The cdx may be a wild type protein appropriate for the species from which the cells are derived, or a mutant form of the protein. | 11-04-2010 |
20100267140 | SOLUBLE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF - The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF | 10-21-2010 |
20100249025 | PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR - The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity. | 09-30-2010 |
20100239637 | CONTACT LENS DRUG DELIVERY DEVICE - The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner. | 09-23-2010 |
20100227823 | METHODS FOR REGULATING ANGIOGENESIS AND VASCULAR INTEGRITY USING TRK RECEPTOR LIGANDS - The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample. | 09-09-2010 |
20100222371 | PREVENTION OF SURGICAL ADHESIONS - The present invention relates to methods for treatment (particularly the prevention or suppression) of formation or reformation of adhesions, particularly in the peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma. The invention provides methods useful for inhibiting, suppressing or ameliorating adhesion formation in mammals, including humans wherein an individual is administered a compound selected from the group consisting of sunitinib malate, axitinib, semaxanib, sorafenib, ZD1839, and erlotinib. The invention applies to human and veterinary applications. The inventive method has been shown to be especially effective in preventing adhesion formation in the peritoneum following surgery. | 09-02-2010 |
20100221266 | METHODS TO REGULATE MIRNA PROCESSING BY TARGETING LIN-28 - The present invention relates generally to methods to regulate microRNA (miRNA) biogenesis, in particular the regulation of the processing of pri-miRNA to mature miRNA by Lin-28 and/or variants such as Lin28B. In particular, the present invention relates to methods and compositions comprising at least one agent which inhibits Lin-28 function or activity and/or expression to increase the processing of pri-mRNA to mature miRNA. More specifically, one aspect of the invention is directed to treating and/or preventing cancer in a subject by administering an agent that inhibits Lin-28 activity or expression to a subject, preferably a human subject. | 09-02-2010 |
20100209396 | Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells - The present invention provides methods for inducing differentiation of a stem cell, such as an embryonic stem cell, into a hematopoietic stem cell, by expressing a cdx gene and/or a hox gene. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. | 08-19-2010 |
20100203143 | SYSTEMS AND METHODS FOR NANOMAGNETIC ACTUATION OF MOLECULAR CELL SIGNALING - The present invention relates to signaling mechanisms that transduce magnetic inputs into physiological cellular outputs. More particularly, the present invention relates to systems and methods for non-invasively controlling cellular signaling functions and behaviors by harnessing receptor-mediated and intracellular molecular-mediated signal transduction using nanomagnetic cellular switches. | 08-12-2010 |
20100158855 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. | 06-24-2010 |
20100152704 | Method for Intravesical Drug Delivery - Implant devices for intravesical administration and local drug delivery. The device has a body which includes a hollow tube formed of a biocompatible material; at least one reservoir in the tube which contains a drug; and one or more apertures through which the drug can be released. The device is configured for minimally invasive insertion into a body cavity, such as the bladder. The hollow tube may be elastomeric to permit the device to be elastically deformed from its initial shape into an elongated shape for passage through a catheter, where following such passage the device can return to or toward its initial shape to facilitate retention of the device in the body cavity. The body may have a narrow, elongated shape effective to permit insertion of the drug delivery device through a catheter without necessarily deforming the body, yet include flexible projections which effect retention within the body cavity. | 06-17-2010 |
20100144603 | METHODS AND USES THEREOF OF PROSAPOSIN - The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and/or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor/cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development. | 06-10-2010 |
20100111924 | Chromosomal Modification Involving the Induction of Double-Stranded DNA Cleavage and Homologous Recombination at the Cleavage Site - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases. | 05-06-2010 |
20100111894 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. | 05-06-2010 |
20100105151 | Novel Druggable Regions in the Dengue Virus Envelope Glycoprotein and Methods of Using the Same - The present invention relates to novel druggable regions discovered in dengue virus envelope glycoprotein, or dengue virus E protein, which is a class II viral E protein. The present invention further relates to methods of using the druggable regions to screen potential candidate therapeutics for diseases caused by viruses having class II E proteins, e.g. viral fusion inhibitors. | 04-29-2010 |
20100105136 | CHIMERIC T-CELL RECEPTORS AND T-CELLS TARGETING EGFRVIII ON TUMORS - Chimeric T-cell receptor proteins have been produced in cells by the construction of nucleic acids and vectors, and the transfection of the vectors into cells. The chimeric proteins comprise, as an extracellular binding portion, a single chain antibody portion that binds to EGFRvIII, a transmembrane portion derived from human CD8α or CD28, and an intracellular signaling portion derived from human CD3ζ. The invention includes nucleic acids, vectors and cells associated with the production of the chimeric membrane protein, as well as methods to treat rumors bearing EGFRvIII, a mutant epidermal growth factor receptor. | 04-29-2010 |
20100105071 | METHODS FOR PREDICTING THE ONSET OF MENARCHE - Embodiments of the invention provide methods for predicting the onset of menarche, i.e. a females first menstrual period, through the measurement of salivary hormone levels (e.g. 17-β estradiol, testosterone, progesterone, and/or 17 hydroxy-progesterone (17-OHP)). In particular, the methods described herein enable a reliable determination that menarche will, or will not occur, within varied time intervals, e.g. 1 to 30 days, 1 to 45 days, 1 to 60 days and 1 to 90 days. Diagnostic kits and products of manufacture comprising the kits are also provided. | 04-29-2010 |
20100069251 | METHODS FOR PRODUCING EMBRYONIC STEM CELLS FROM PARTHENOGENETIC EMBRYOS - Means for producing embryonic stem (pES) cells which have a heterozygous genome that is matched to an individual donor are provided. In one embodiment, a means for the generation and isolation of parthenogenetic embryonic stem (pES) cells which have regions of heterozygosity that are fully matched to the oocyte donor at the MHC loci (e.g. (h-)p(MI)ES cells is provided. This is in contrast to the traditional methods of parthenogenesis that generate parthenogenetic embryonic stem (pES) cells having a substantially homozygous haploidentical set of chromosomes that are homozygous at the MHC loci. | 03-18-2010 |
20100048862 | Ferroportin1 nucleic acids, proteins, antibodies and methods - Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in | 02-25-2010 |
20100048705 | METHODS OF TREATING AND PREVENTING NEOVASCULARIZATION WITH OMEGA-3 POLYUNSATURATED FATTY ACIDS - Disclosed are methods for treating or preventing ocular neovascularization in a subject at risk. The method comprises administering to the subject an effective amount of omega-3 polyunsaturated fatty acid to thereby treat or prevent the ocular neovascularization. This method is suitable for treating or preventing retinopathy of prematurity, retina vein occlusion, sickle cell retinopathy, choroidal neovascularization, radiation retinopathy, microangiopathy, retinal hyperoxia, diabetic retinopathy, and age related macular degeneration. Preferably the methods are applied to premature infants, especially those exposed to high levels of oxygen, to treat or prevent ocular neovascularization results from retinopathy of prematurity. Preferably, the omega-3 polyunsaturated fatty acid is administered at high dose, periodically (e.g. from birth) over a prolonged period of time, until the eye is fully vascularized, or to the age of 1 year. Appropriate routes of administration include oral and intravenous administration. Suitable omega-3 polyunsaturated fatty acids include docosahexaenoic acid and eicosapentaenoic acid. These agents can be administered in a pharmaceutically acceptable carrier, e.g. one which contains an anti-oxidant for the omega-3 polyunsaturated fatty acid. | 02-25-2010 |
20100040584 | METHODS FOR PROMOTING NEOVASCULARIZATION - The success of tissue engineering and therapeutic neovascularization depends on the development of a microvascular network. The present invention provides methods for promoting neovascularization in tissue engineering constructs, tissue repair, and wound healing comprising endothelial and mesenchymal progenitor cells. | 02-18-2010 |
20100035843 | METHODS FOR ATTENUATING ALLERGEN-INDUCED AIRWAY HYPERREACTIVITY USING CD1D DEPENDENT ANTAGONISTS - The present invention is directed to a method of inhibiting allergen-induced airway CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Methods of the invention are useful for treatment and prevention of air-way hyperactivity caused by an allergen, and results in the attenuation of CD1d-restricted immune responses, including treatment of hay fever and asthma are due to air-way hyperactivity, and for systemic administration to attenuate ongoing immune responses. Preferably, these compositions are in a form intended for administration via nasal passages or directly inhaled to the air-ways. | 02-11-2010 |
20090322783 | Method and apparatus for displaying information - A method for displaying large amounts of information. The method includes the steps of forming a spatial layout of tiles each corresponding to a representative reference element; mapping observed elements onto the spatial layout of tiles of representative reference elements; assigning a respective value to each respective tile of the spatial layout of the representative elements; and displaying an image of the spatial layout of tiles of representative elements. Each tile includes atomic attributes of representative elements. The invention also relates to an apparatus for displaying large amounts of information. The apparatus includes a tiler forming a spatial layout of tiles, each corresponding to a representative reference element; a comparator mapping observed elements onto said spatial layout of tiles of representative reference elements; an assigner assigning a respective value to each respective tile of said spatial layout of representative reference elements; and a display displaying an image of the spatial layout of tiles of representative reference elements. | 12-31-2009 |